Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

Enrica Marchi, Luca Paoluzzi, Luigi Scotto, Venkatraman E. Seshan, Jasmine M. Zain, Pier Luigi Zinzani, Owen A. O'Connor

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Fingerprint

Dive into the research topics of 'Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences